Beilu Pharmaceutical

Beilu Pharmaceutical (alternatively as Beilu Pharmaceuticals; short for Beijing Beilu Pharmaceutical Co., Ltd. ), simply known as Beilu, is a Chinese pharmaceutical company founded in 1992. It went public on the Shenzhen Stock Exchange in 2009 and underwritten by UBS. Prior to that, it was listed on the NEEQ. The company mainly produces gadopentetate dimeglumine injections, and Iohexol injections.

Beilu Pharma is headquartered in Beijing, and was financed by Infotech in 2008. It had reached required standards to float shares on the Shenzhen second board market in May 2009. In October, Beilu officially landed on the ChiNext under the ticker symbol "SHE: 300016".

In 2014, Beilu Pharma invested 30 million yuan in Geneseeq Technology. In May 2016, it established an industry buyout fund worth 610 million yuan. In June, the company increased its investment in Geneseeq. Its net profit surpassed 118 million yuan in 2017. In 2020, Beilu raised $70.42 million.